Wechselwirkungen · MenQuadfi
MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine MenACWY · Abschnitt 4.5 · PDF-Seite 5
HOS-144193 · Präparat HOS-099130
In toddlers aged 12-23 months, MenQuadfi can be co-administered with the measles-mumps-rubella vaccine (MMR) and varicella vaccine (V), DTaP vaccines, including combination DTaP vaccines with IPV, HepB, and Hib such as DTaP-IPV-HepB-Hib (Hib conjugated to tetanus toxoid) vaccine, PCV10, and 13-valent pneumococcal polysaccharide conjugated vaccine (PCV13). When MenQuadfi was administered concomitantly with PCV13 in toddlers aged 12-23 months, lower hSBA GMTs on day 30 post-dose for serogroup A were observed. The clinical relevance of this observation is unknown. As a precaution in toddlers initiating MenQuadfi vaccination at 12-23 months of age and who are at high risk for serogroup A disease, consideration might be given for administration of MenQuadfi and PCV13 vaccines separately.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:00:00Z · SHA-256 ebec4745bfdc370a0e03b2fca938d4349a0aa60a9b6f828972f5fba03ef36517 · Passage 0360b4df9f7d320e63b726708f85de7fc4d7685edf4d5e64c4f1f2a8e82bacbf · Zeichen 523–1316 im Abschnitt